Emerging retatrutide, a twin -action medication targeting both GLP-1 and GIP receptors, is sparking considerable interest within the weight loss community. Early clinical research have demonstrated substantial decreases in physical size and advancements in health markers for patients with obesity . Scientists believe this novel approach could mark